Eiko Lifesciences
NARENDRAINVESTMENTSLTD NSE
Eiko Lifesciences
ChemicalsNSE: NARENDRAINVESTMENTSLTD BSE: 540204 Specialty Chemicals
Key Fundamentals
MicrocapSpecialty ChemicalsChemicalsMarket Cap
₹65.69 Cr
Volatility
Moderate
P/E Ratio
11.8
EBITDA
₹8.40 Cr
Return on Equity
7.63%
Debt to Equity
0.07
Book Value
₹45.32
EPS
₹0.6
52W High
₹64.44
52W Low
₹44.75
Tapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Strengths
3- Company is almost debt free.
- Stock is trading at 0.95 times its book value
- Company is expected to give good quarter
Weaknesses
2- Though the company is reporting repeated profits, it is not paying out dividend
- Promoter holding is low: 39.9%
Growth Rate
Revenue Growth
39.84% lower than
3Y
Net Income Growth
130% higher than
3Y
Cash Flow Change
-19.06% lower than
3Y
ROE
87.47% higher than
3Y
ROCE
86.83% higher than
3Y
EBITDA Margin (Avg.)
72.96% higher than
3Y
Quarterly Results
| Particulars | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 3.2 | 0.62 | 0.56 | 0.84 | 10.75 | 8.16 | 7.49 | 11.27 | 10.71 | 11.67 | 11.98 | 18.34 | 16.75 |
| Expenses | 4.55 | 1.53 | 0.42 | 0.89 | 10.35 | 7.73 | 6.86 | 9.95 | 9.2 | 9.9 | 10.1 | 16.08 | 14.82 |
| Operating Profit | -1.35 | -0.91 | 0.14 | -0.05 | 0.4 | 0.43 | 0.63 | 1.32 | 1.51 | 1.77 | 1.88 | 2.26 | 1.93 |
| OPM % | -42.19% | -146.77% | 25% | -5.95% | 3.72% | 5.27% | 8.41% | 11.71% | 14.1% | 15.17% | 15.69% | 12.32% | 11.52% |
| Other Income | 0.01 | -0.04 | 0.05 | 0.01 | 0.26 | 0.13 | 0.12 | 0.64 | 0.27 | 0.3 | 0.35 | 0.13 | 0.45 |
| Interest | 0.08 | 0.03 | 0.01 | 0.1 | 0.03 | 0.04 | 0.03 | 0.07 | 0.05 | 0.1 | 0.07 | 0.12 | 0.13 |
| Depreciation | 0.05 | 0.05 | 0.04 | 0.04 | 0.17 | 0.16 | 0.16 | 0.25 | 0.25 | 0.26 | 0.26 | 0.25 | 0.25 |
| PBT | -1.47 | -1.03 | 0.14 | -0.18 | 0.46 | 0.36 | 0.56 | 1.64 | 1.48 | 1.71 | 1.9 | 2.02 | 2 |
| Tax % | -25.85% | -28.16% | 28.57% | -22.22% | 26.09% | 27.78% | 25% | 23.78% | 25% | 24.56% | 24.74% | 25.74% | 24.5% |
| Net Profit | -1.08 | -0.74 | 0.1 | -0.13 | 0.37 | 0.28 | 0.42 | 1.25 | 1.11 | 1.29 | 1.43 | 1.5 | 1.51 |
| EPS in Rs | -0.92 | -0.64 | 0.09 | -0.08 | 0.3 | 0.22 | 0.33 | 0.84 | 0.66 | 0.79 | 0.88 | 0.91 | 0.91 |
Profit & Loss
| Particulars | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|
| Sales | 2.36 | 4.27 | 10.4 | 37.66 | 52.57 | 58.74 |
| Expenses | 1.98 | 4.95 | 14.91 | 34.89 | 45.24 | 50.9 |
| Operating Profit | 0.38 | -0.68 | -4.51 | 2.77 | 7.33 | 7.84 |
| OPM % | 16.1% | -15.93% | -43.37% | 7.36% | 13.94% | 13.35% |
| Other Income | 0.04 | 0.04 | 0.01 | 1.2 | 1.16 | 1.23 |
| Interest | 0.09 | 0.19 | 0.24 | 0.17 | 0.36 | 0.42 |
| Depreciation | 0.08 | 0.17 | 0.19 | 0.74 | 1.02 | 1.02 |
| PBT | 0.25 | -1 | -4.93 | 3.06 | 7.11 | 7.63 |
| Tax % | 20% | -21% | -26.77% | 24.51% | 25.18% | — |
| Net Profit | 0.2 | -0.78 | -3.62 | 2.32 | 5.32 | 5.73 |
| EPS in Rs | 0.31 | -0.69 | -2.98 | 1.86 | 3.71 | 3.49 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | — |
Balance Sheet
| Particulars | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Equity Capital | 3.82 | 3.82 | 3.82 | 13.76 | 14.35 |
| Reserves | 1.74 | 1.1 | -0.87 | 43.03 | 54.44 |
| Borrowings | 1.74 | 1.37 | 1.61 | 2.76 | 4.73 |
| Other Liabilities | 3.66 | 3.01 | 7.49 | 6.56 | 15.85 |
| Total Liabilities | 10.96 | 9.3 | 12.05 | 66.11 | 89.37 |
| Fixed Assets | 1.68 | 1.71 | 1.75 | 23.12 | 22.1 |
| CWIP | 0 | 0 | 0 | 0 | 0 |
| Investments | 3.17 | 1.72 | 0.1 | 7.15 | 15.29 |
| Other Assets | 6.11 | 5.87 | 10.2 | 35.84 | 51.98 |
| Total Assets | 10.96 | 9.3 | 12.05 | 66.11 | 89.37 |
Cash Flow
| Particulars | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Operating | 0 | 0.16 | -0.33 | 2.78 | 2.25 |
| Investing | 0 | -0.3 | -0.71 | -11.3 | -8.63 |
| Financing | 0 | -0.55 | 0.95 | 6.96 | 8.21 |
| Net Cash Flow | 0 | -0.69 | -0.09 | -1.57 | 1.83 |
| Free Cash Flow | 0 | -0.04 | -0.56 | -7.51 | 2.25 |
| CFO/OP | 0 | -26 | 7 | 112 | 50 |
Ratios
| Particulars | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Debtor Days | 226 | 73.51 | 41.41 | 105 | 140 |
| Inventory Days | 820 | 288 | 154 | 64.48 | 35.09 |
| Days Payable | 606 | 174 | 185 | 36.99 | 111 |
| Cash Conversion Cycle | 440 | 187 | 10.72 | 132 | 64.46 |
| Working Capital Days | 80.42 | -1.71 | -152 | 144 | 128 |
| ROCE % | — | -11.83% | -105.39% | — | 11.12% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Eiko Lifesciences insights
64 extracted metrics + investor summaries across FY12–FY26.
Documents
1
Non Applicability Of Annual Disclosure As Per SEBI Circular - Fund Raising By Issuance Of Debt Securities By Large Corporates.
9 Apr - On 31 March 2026, Eiko Lifesciences was not a Large Corporate under SEBI debt rules. 9 Apr - On 31 March 2026, Eiko Lifesciences was not a Large Corporate under SEBI debt rules.
2
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
8 Apr - Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations 2018 for the quarter and year ended on 31st March, 2026 received from M/s. Bigshare … 8 Apr - Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations 2018 for the quarter and year ended on 31st March, 2026 received from M/s. Bigshare …
4
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
27 Feb - Of allotment of 2,01,605 number of equity shares pursuant to exercise of options under PPL - ESOP Plan 2021 27 Feb - Of allotment of 2,01,605 number of equity shares pursuant to exercise of options under PPL - ESOP Plan 2021
5
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
26 Feb - Lenus Finvest allotted 175,000 shares and 150,000 warrants on 24 Feb 2026; promoter stake becomes 17.71%. 26 Feb - Lenus Finvest allotted 175,000 shares and 150,000 warrants on 24 Feb 2026; promoter stake becomes 17.71%.
Frequently Asked Questions about Eiko Lifesciences
What does Eiko Lifesciences Ltd do?
Incorporated in 2021, Eiko LifeSciences
Ltd manufacturing & sells Specialty
Chemical and Fine Chemicals[1]
Where is Eiko Lifesciences Ltd (540204) listed?
Eiko Lifesciences Ltd trades as NARENDRAINVESTMENTSLTD on the NSE and under code 540204 on the BSE.
Which sector does Eiko Lifesciences Ltd belong to?
Eiko Lifesciences Ltd is classified under the Chemicals sector, in the Specialty Chemicals industry.
What is the market capitalisation of Eiko Lifesciences Ltd?
Eiko Lifesciences Ltd has a market capitalisation of ₹65.69 Cr, which places it in the Small Cap band.
What is the PE ratio of Eiko Lifesciences Ltd?
Eiko Lifesciences Ltd trades at a PE ratio of 11.80, on earnings per share of ₹0.6, against a book value of ₹45.32 per share.
What is the 52-week high and low of Eiko Lifesciences Ltd?
Over the last 52 weeks Eiko Lifesciences Ltd has traded between ₹44.75 and ₹64.44.
What is the Return on Equity (ROE) of Eiko Lifesciences Ltd?
Eiko Lifesciences Ltd reported a return on equity of 7.63%. Its debt-to-equity ratio is 0.07.
Company Information
Incorporated in 2021, Eiko LifeSciences Ltd manufacturing & sells Specialty Chemical and Fine Chemicals[1]
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/540204.md for Eiko Lifesciences Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.